Filing Details

Accession Number:
0001209191-15-068040
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-08-26 16:59:23
Reporting Period:
2015-08-24
Filing Date:
2015-08-26
Accepted Time:
2015-08-26 16:59:23
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1631650 Aimmune Therapeutics Inc. AIMT Pharmaceutical Preparations (2834) 452748244
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1581754 B. James Tananbaum 101 California Street
Suite 4100
San Francisco CA 94111
No No Yes No
1594912 Foresite Capital Management Ii, Llc 101 California Street
Suite 4100
San Francisco CA 94111
No No Yes No
1594914 Foresite Capital Fund Ii, L.p. 101 California Street
Suite 4100
San Francisco CA 94111
No No Yes No
1645157 Foresite Capital Management Iii, Llc 101 California Street
Suite 4100
San Francisco CA 94111
No No Yes No
1645158 Foresite Capital Fund Iii, L.p. 101 California Streeet
Suite 4100
San Francisco CA 94111
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.0001 Par Value Acquisiton 2015-08-24 25,485 $19.65 355,020 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock, $0.0001 Par Value 4,087,900 Indirect See Footnote
Footnotes
  1. Shares are owned directly by Foresite Capital Fund II, L.P. ("FCF II"). Foresite Capital Management II, LLC ("FCM II"), the general partner of FCF II, may be deemed to have the sole voting and dispositive power over these shares. James Tananbaum (" Mr. Tananbaum"), in his capacity as managing member of FCM II, may be deemed to have the sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM II and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM II and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.
  2. Shares are owned directly by Foresite Capital Fund III, L.P. ("FCF III"). Foresite Capital Management III, LLC ("FCM III"), the general partner of FCF III, may be deemed to have the sole voting and dispositive power over these shares. James Tananbaum (" Mr. Tananbaum"), in his capacity as managing member of FCM III, may be deemed to have the sole voting and dispositive power over these shares. Each Reporting Person disclaims the existence of a "group." Each of FCM III and its members and Mr. Tananbaum disclaims beneficial ownership of any of these shares except to the extent of any pecuniary interest therein, and the filing of this report is not an admission that FCM III and its members or Mr. Tananbaum is the beneficial owner of these shares for purposes of Section 16 or any other purpose.